RxDoctor Payments Data

Stuart Wong, MD

Medical Oncology · Milwaukee, WINPI 1265483291

Payments from drug & device makers

What this record shows

This record is dominated by education: $33 of the $33 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Merck. That places this record below the midpoint for medical oncology clinicians in WI, where the typical reported total is $220.

$33in general payments, 2019–2025

Across 3 payments — averaging $10.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$33
$14,940,629in research payments, 2019–2025

Across 128 payments — averaging $116,724 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$14.1M
  • Novartis$401K
  • GSK$144K
  • AVEO Pharmaceuticals, Inc.$120K
  • Regeneron$115K
  • Coherus Oncology, Inc.$38K
  • plus $2K from 1 others

What the payments were for

  • Education$33100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck3$33

How this compares

$33 in reported general payments places this provider in the 20th percentile of 54 medical oncology providers in Wisconsin.

See all medical oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$28,789
Medicare patients
96
Services billed
347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MekinistTrametinib Dimethyl Sulfoxide12$173,171
TafinlarDabrafenib Mesylate12$158,134
GilotrifAfatinib Dimaleate11$112,542
Ondansetron Hcl43$531
Dexamethasone19$293
Olanzapine18$115

Paid to pharmacies, not to this prescriber.

Other medical oncology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →